tbuckley/cabot-search huggingface dataset:
Abstract B28: Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR-mutant lung cancer
Authors: Milica Momcilovic, Sean T. Bailey, Jason T. Lee, Clara Magyar, Daniel Braas, Thomas Graeber, Francesco Parlati, Susan Demo, Konstyantyn Krysan, Tonya C. Walser, Steven M. Dubinett, Saman Sadeghi, Heather R. Christofk, David B. Shackelford
Journal: Clinical Cancer Research (2018)

Abstract Cancer cells exhibit increased use of nutrients, including glucose and glutamine, to support the bioenergetic and biosynthetic demands of proliferation. We tested the small-molecule inhibitor of glutaminase CB-839 in combination with erlotinib on epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) as a therapeutic strategy to simultaneously impair cancer glucose and glutamine utilization and thereby suppress tumor growth. Here, we show that CB-839 cooperates with erlotinib to drive energetic stress and activate the AMP-activated protein kinase (AMPK) pathway in EGFR (del19) lung tumors. Tumor cells undergo metabolic crisis and cell death, resulting in rapid tumor regression in vivo in mouse NSCLC xenografts. Consistently, positron emission tomography (PET) imaging with 18F-fluoro-2-deoxyglucose (18F-FDG) and 11C-glutamine (11C-Gln) of xenografts indicated reduced glucose and glutamine uptake in tumors following treatment with CB-839 + erlotinib. Therefore, PET imaging with 18F-FDG and 11C-Gln tracers can be used to noninvasively measure metabolic response to CB-839 and erlotinib combination therapy. Citation Format: Milica Momcilovic, Sean T. Bailey, Jason T. Lee, Clara Magyar, Daniel Braas, Thomas Graeber, Francesco Parlati, Susan Demo, Konstyantyn Krysan, Tonya C. Walser, Steven M. Dubinett, Saman Sadeghi, Heather R. Christofk, David B. Shackelford. Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR-mutant lung cancer [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr B28.
Cyclin A and cyclin D1 as significant prognostic markers in Egyptian colorectal cancer patients
Authors: Abeer A. Bahnassy, Abdel-Rahman N. Zekri, Soumaya El-Houssini, Moustafa R. Mahmoud, Amal M. El-Shehaby, Mostafa El-Serafi
Journal: Cancer Research (2004)

2588  Colorectal cancer (CRC) is a common cancer allover the world. Aberrations in the cell cycle checkpoints have been shown to be of prognostic significance in CRC The expression of cyclin D1, cyclin A, histone H3 and Ki-67 was examined in 60 CRC cases for co-regulation and impact on overall survival (OS) using immunohistochemistry, Southern blot and in situ hybridization techniques. Immunoreactivity was evaluated semi quantitatively by determining the staining index (SI) of the studied proteins. There was a significant correlation between cyclin D1 gene amplification and protein overexpression (concordance= 63.6%) and between Ki-67 and the other studied proteins. The SIs for Ki-67, cyclin A & D1 were higher in large, poorly differentiated tumors. The SI of cyclin D1 was significantly higher in cases with deeply invasive tumors and nodal metastasis. Overexpression of cyclin A& D1 and amplification of cyclin D1 were associated with reduced OS. Multivariate analysis shows that cyclin D1 &A are two independent prognostic factors in CRC patients. In conclusion, loss of cell cycle checkpoints control is common in CRC. Cyclin A& D1 are superior independent indicators of poor prognosis in CRC patients. Therefore, they may help in predicting the clinical outcome of those patients on an individual basis and could be considered important therapeutic targets
Allogeneic Hematopoietic Stem Cell Transplantation for Patients over 60 Years with Acute Myeloid Leukemia: A Single Center Donor Comparison
Authors: Raynier Devillier, Sabine Furst, Jerome Rey, Angela Granata, Aude Charbonnier, Samia Harbi, Evelyne D'Incan, Thomas Pagliardini, Catherine Faucher, Claude Lemarie, Colombe Saillard, Faezeh Legrand, Boris Calmels, Bilal Mohty, Valerio Maisano, Christian Chabannon, Pierre Jean Weiller, Norbert Vey, Didier Blaise
Journal: Blood (2017)
The Incidence and Impact of Clostridioides Difficile Infection (CDI) on Outcomes after Allogeneic Hematopoietic Cell Transplant (alloHCT) - a CIBMTR Study
Authors: Muthalagu Ramanathan, Bipin B. Savani, Naya He, Soyoung Kim, Min Chen, Roy Chemaly, Christopher E Dandoy, Miguel-Angel Perales, Marcie L. Riches, Celalettin Ustun
Journal: Blood (2021)
<i>Post-Transplant High Dose Cyclophosphamide and Bortezomib As Graft-Versus-Host Disease Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation</i>
Authors: Benedetto Bruno, Frank Cirrone, Kelli Cole, Kelsey Stocker, Maher Abdul-Hay, J Andres Suarez-Londono, Tsivia Hochman, Judith Goldberg, A Samer Samer Al-Homsi
Journal: Blood (2021)
Germline and Somatic Variants of CSF3R Define Distinct Myeloid Neoplasia Syndromes
Authors: Tariq Kewan, Hrishikesh M Mehta, Carmelo Gurnari, Waled Bahaj, Simona Pagliuca, Suresh Kumar Balasubramanian, Bhumika J. Patel, Anjali Advani, Valeria Visconte, Hetty E. Carraway, Seth J. Corey, Jaroslaw P. Maciejewski
Journal: Blood (2021)
<i>MGA</i> deletion Leads to Richter's Transformation Via NME1
Authors: Prajish Iyer, Bo Zhang, Tingting Liu, Meiling Jin, Kevyn Hart, Joo Y. Song, John Chan, Raju Pillai, Tanya Siddiqi, Alexey V. Danilov, Steven T. Rosen, Lili Wang
Journal: Blood (2021)
An Alternative Technique of Intraoperative Identification of Multiple Muscular Ventricular Septal Defects
Authors: Ujjwal Kumar Chowdhury, Niwin George, Lakshmi Kumari Sankhyan, Gaind Saurabh, Shweta Sharma, Shikha Goja M, Niraj Nirmal Pandey
Journal: Clinical Cardiology and Cardiovascular Interventions (2021)

We propose the passage of a thick black braided silk SUTUPAK silk suture (Ethicon, Somerville, NJ) through the additional muscular ventricular septal defects to facilitate patch closure of the multiple muscular ventricular septal defects.
Circular RNAs in acute myeloid leukemia
Authors: Vijendra Singh, Mohammed Hafiz Uddin, Jeffrey A. Zonder, Asfar S. Azmi, Suresh Kumar Balasubramanian
Journal: Molecular Cancer (2021)

Abstract Although mechanistic studies clarifying the molecular underpinnings of AML have facilitated the development of several novel targeted therapeutics, most AML patients still relapse. Thus, overcoming the inherent and acquired resistance to current therapies remains an unsolved clinical problem. While current diagnostic modalities are primarily defined by gross morphology, cytogenetics, and to an extent, by deep targeted gene sequencing, there is an ongoing demand to identify newer diagnostic, therapeutic and prognostic biomarkers for AML. Recent interest in exploring the role of circular RNA (circRNA) in elucidating AML biology and therapy resistance has been promising. This review discerns the circular RNAs’ evolving role on the same scientific premise and attempts to identify its potential in managing AML.
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry
Authors: Zobair M. Younossi, Yusuf Yilmaz, Ming-Lung Yu, Vincent Wai-Sun Wong, Marlen Castellanos Fernandez, Vasily A. Isakov, Ajay K. Duseja, Nahum Mendez-Sanchez, Yuichiro Eguchi, Elisabetta Bugianesi, Patrizia Burra, Jacob George, Jian-Gao Fan, George V. Papatheodoridis, Wah Kheong Chan, Khalid Alswat, Hamid S. Saeed, Ashwani K. Singal, Manuel Romero-Gomez, Stuart C. Gordon, Stuart K. Roberts, Mohamed El Kassas, Marcelo Kugelmas, Janus P. Ong, Saleh Alqahtani, Mariam Ziayee, Brian Lam, Issah Younossi, Andrei Racila, Linda Henry, Maria Stepanova
Journal: Clinical Gastroenterology and Hepatology (2021)
Abstract 9399: A Targeted Proteomic Approach Identifies Novel Biomarkers Associated With Risk of Myocardial Infarction in Post-Menopausal Women
Authors: Siddharth M Patel, David A Morrow, Minao Tang, Frederick K Kamanu, KyungAh Im, Marc S Sabatine, Michelle L Odonoghue
Journal: Circulation (2021)

Introduction: There may be unique pathways that contribute to heart disease in women. We used proteomics to evaluate the association between a panel of biomarkers and risk of incident MI in post-menopausal women and thus to inform risk prediction and potential disease biology. Methods: We analyzed 184 candidate biomarkers (Olink CVD II/III) in LOFT, a randomized trial of an osteoporosis drug in post-menopausal women. Cases and controls without prevalent CV disease were matched by age and follow-up time (123 MI cases, 123 controls). A Benjamini-Hochberg correction was applied for false discovery (adj P value &lt;0.05). Conditional logistic regression was adjusted for the ACC/AHA pooled cohort equations (PCE). Results: 16 biomarkers assessed at baseline were associated with incident MI at the FDR threshold (Fig). After multivariable adjustment, 8 markers remained significantly associated with incident MI, including BNP (adj OR per SD 2.52, 95% CI 1.49-4.28), NT-proBNP (adj OR 2.41, 95% CI 1.43-4.08) and metalloproteinases including MMP-2 (adj OR 1.86, 95% CI 1.08-3.22) and MMP-12 (adj OR 1.55, 95% CI 1.02-2.37; Fig). Network analyses suggested these markers were overall strongly concentrated in pathways of inflammation, cellular movement and immune cell trafficking. Conclusions: A targeted proteomic approach identified markers of inflammation and immune cell trafficking as predictors of MI in post-menopausal women independent of traditional risk markers. Metalloproteinases, markers of plaque rupture and erosion, may provide insights into plaque biology and atherogenesis in women and warrant further investigation.
A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma
Authors: Mingzhi Zhang, Xiaorui Fu, Huimin Meng, Min Wang, Yu Wang, Lei Zhang, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Xiaolong Wu, Guifang Pan, Yanmei Zhao, Yu-Sheng Chen, Fengtao You, Lin Yang
Journal: Blood (2021)
Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myélome (IFM)
Authors: Magaret Macro, Cyrille Touzeau, Clara Mariette, Salomon Manier, Sabine Brechignac, Laure Vincent, Benjamin Hebraud, Olivier Decaux, Samantha Schulmann, Caroline Bureau Lenoir, Pascal Godmer, Jean-Jacques Parienti, Xavier Leleu
Journal: Blood (2021)
Abstract 13432: Predictors of Adverse Outcomes in Patients With Acute Pericarditis
Authors: Alessandra Vecchie, Juan Guido Chiabrando, Megan Dell, George Wohlford, Sherrie Tafuri, John Paolini, Benjamin W Van Tassell, Anna Beutler, Tamas Gal, Fabrizio Montecucco, Antonio Abbate
Journal: Circulation (2019)

Introduction: Acute pericarditis is the most common presentation of pericardial diseases. Although generally characterized by benign prognosis, recurrences, constriction, and tamponade can occur. H...
A Retrospective Observational Real-World Study of the Characteristics, Genomic Analysis, Treatment Patterns and Outcomes of Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the United States
Authors: John C. Byrd, Jennifer L Gatz, Larry D. Cripe, , Cynthia Lim Louis, Alice S. Mims, Uma Borate, Ashley O. Yocum, Theophilus Gana, Amy Burd
Journal: Blood (2021)
Single Cell Analysis of MYD88 L265P and MYD88 WT Waldenström Macroglobulinemia Patients
Authors: Tina Bagratuni, Foteini Aktypi, Maria Sakkou, Kleio Maria Verrou, Nefeli Mavrianou-Koutsoukou, Dimitrios Patseas, Christine Ivy Liacos, Stamatia Skourti, Alexandra Papadimou, Foteini Theodorakakou, George Kollias, Petros Sfikakis, Maria Gavriatopoulou, Evangelos Terpos, Meletios A. Dimopoulos, Efstathios Kastritis
Journal: Blood (2021)
A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma
Authors: Andreas Stefan Brendlin, Felix Peisen, Haidara Almansour, Saif Afat, Thomas Eigentler, Teresa Amaral, Sebastian Faby, Adria Font Calvarons, Konstantin Nikolaou, Ahmed E Othman
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background To assess the additive value of dual-energy CT (DECT) over single-energy CT (SECT) to radiomics-based response prediction in patients with metastatic melanoma preceding immunotherapy. Material and methods A total of 140 consecutive patients with melanoma (58 female, 63±16 years) for whom baseline DECT tumor load assessment revealed stage IV and who were subsequently treated with immunotherapy were included. Best response was determined using the clinical reports (81 responders: 27 complete response, 45 partial response, 9 stable disease). Individual lesion response was classified manually analogous to RECIST 1.1 through 1291 follow-up examinations on a total of 776 lesions (6.7±7.2 per patient). The patients were sorted chronologically into a study and a validation cohort (each n=70). The baseline DECT was examined using specialized tumor segmentation prototype software, and radiomic features were analyzed for response predictors. Significant features were selected using univariate statistics with Bonferroni correction and multiple logistic regression. The area under the receiver operating characteristic curve of the best subset was computed (AUROC). For each combination (SECT/DECT and patient response/lesion response), an individual random forest classifier with 10-fold internal cross-validation was trained on the study cohort and tested on the validation cohort to confirm the predictive performance. Results We performed manual RECIST 1.1 response analysis on a total of 6533 lesions. Multivariate statistics selected significant features for patient response in SECT (min. brightness, R²=0.112, padj. ≤0.001) and DECT (textural coarseness, R²=0.121, padj. ≤0.001), as well as lesion response in SECT (mean absolute voxel intensity deviation, R²=0.115, padj. ≤0.001) and DECT (iodine uptake metrics, R²≥0.12, padj. ≤0.001). Applying the machine learning models to the validation cohort confirmed the additive predictive power of DECT (patient response AUROC SECT=0.5, DECT=0.75; lesion response AUROC SECT=0.61, DECT=0.85; p&lt;0.001). Conclusion The new method of DECT-specific radiomic analysis provides a significant additive value over SECT radiomics approaches for response prediction in patients with metastatic melanoma preceding immunotherapy, especially on a lesion-based level. As mixed tumor response is not uncommon in metastatic melanoma, this lends a powerful tool for clinical decision-making and may potentially be an essential step toward individualized medicine.
In Patients with Acute Myeloid Leukemia, Hidac Administered on Days 1, 2 and 3 of Consolidation Course Is As Efficacious As Hidac Given on Days 1, 3 and 5, but Is Better Tolerated
Authors: Baher Krayem, Avraham Frisch, Nurit Horesh, Ronit Leiba, Tsila Zuckerman, Yishai Ofran
Journal: Blood (2021)
Abstract 14373: Artificial Intelligence for COVID-19 Chest X-rays: Early Detection of COVID-19 Pneumonia and Prediction of Patient Prognosis
Authors: Gilberto J Aquino, Jordan Chamberlin, Dhiraj Baruah, Ismail Kabakus, Nathan Leaphart, Namrata Paladugu, Anand Mulji, Sophia Nance, Logan Fitzpatrick, Matthew Fiegel, Sean Brady, Philipp Hoelzer, Mathis Zimmermann, Joseph Schoepf, Jeremy R Burt
Journal: Circulation (2021)

Introduction/Hypothesis: To validate an AI algorithm for rapid detection of COVID-19 pulmonary complications and prediction of negative 30-day outcomes in COVID-suspicious patients. Methods: We included 2000 chest X-rays (CXR) from patients who had a COVID-19 RT-PCR test within 14 days of the CXR. A deep learning CNN (AI-RAD Companion, Siemens) previously trained for non-COVID pneumonia was used to analyze the CXRs. A total of 1544 CXRs were first used to train the AI with COVID cases. Then, a randomized modified internal holdout of 456 patients (236 positive, 220 negative) were used as test cohort. AI results detect the presence of COVID-19 lung disease (CLD) and also report a 1 to 10 AI severity score. Positive RT-PCR within 14 days of the CXR was used as the ground-truth for COVID diagnosis. Radiologic assessment by three cardiothoracic radiologists was used to detect the presence of CLD and generate a 1 to 10 expert severity score. All-cause mortality within 30 days of the CXR was recorded. Receiver-operating characteristic (ROC) curve analysis was performed and the area under the curve (AUC) was reported. Concordance metrics included intraclass correlation coefficient (ICC) for comparison of AI and expert results. Results: In COVID+ patients, AI demonstrated a sensitivity of 99% (205/207) , specificity of 62% (18/29), PPV of 95% (205/216), and NPV of 90% (18/20), for the detection of CLD. Amongst COVID+ patients, the AI severity score had excellent agreement with the expert severity score for lung involvement (ICC=0.89, 95% CI 0.86-0.92). There were 70 deaths in the test cohort (15.3%). The AI severity score had an excellent ability to predict all-cause mortality (AUC=0.832 vs expert AUC=0.844, p &gt;0.05). Conclusions: This CXR AI tool had an excellent sensitivity for detection of COVID-19 lung disease in PCR-positive patients and excellent correlation with expert analysis. AI severity score was able to strongly predict 30-day patient all-cause mortality.
Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myeloid Leukemia
Authors: Lih-Wen Mau, Jaime M. Preussler, Christa Meyer, Mary Senneka, Sophie Wallerstedt, Patricia Steinert, Nandita Khera, Wael Saber
Journal: Blood (2021)
Wolff-Parkinson-White (WPW) Syndrome Catheter Ablation in Prince Sultan Cardiac Center
Authors: Ibrahim Yaseen M Osman, Yahya Alhebaishi, Lamia Alshengeiti, Khalid Dagriri, Adil Asman, Salih Alghamd, Mohammed Mosaad
Journal: Clinical Cardiology and Cardiovascular Interventions (2021)

Despite being one of the most common causes of supraventricular tachycardia in young adult, there are not many studies that highlight the demographics data as well as procedural characteristics of accessory pathway in Saudi Arabia.
The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy
Authors: Paolo F. Caimi, Kirit M. Ardeshna, Erin Reid, Weiyun Z. Ai, Matthew A. Lunning, Jasmine Zain, Melhem Solh, Brad S. Kahl, Mehdi Hamadani
Journal: Blood (2021)
Venetoclax Plus Hypomethylating Agent for the Salvage Treatment of Myeloid Malignancies Relapsing after Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study on Behalf of the Zhejiang Cooperative Group for Blood and Marrow Transplantation
Authors: Fei Gao, Yi Luo, Jian Yu, Huarui Fu, Xiaoyu Lai, Lizhen Liu, Baodong Ye, Jianping Lan, Xiaolu Song, Ying Lu, Lieguang Chen, Yi Chen, Kang Yu, He Huang, Jimin Shi, Yanmin Zhao
Journal: Blood (2021)
Abstract PO-079: Proteomic profiling reveals subtype specific kinase expression in pancreatic cancer
Authors: Yi Xu, Michael East, Ashley Morrison, Gabriela Herrera, Laura Peng, Gary Johnson, Jen Jen Yeh
Journal: Cancer Research (2021)

Abstract Pancreatic adenocarcinoma (PDAC) remains an extremely lethal disease with few effective therapeutic options. Targeted therapy development has remained largely unsuccessful due to complex tumor heterogeneity and better molecular indicators of response are urgently needed. We have previously identified two distinct molecular tumor subtypes in PDAC, basal-like and classical, which are prognostic and dictate response to chemotherapy. We have also developed a patient derived xenograft (PDX) mouse model that maintains the integrity of patient tumor biology and recapitulates primary tumor subtypes in vivo. Here, we aim to utilize multiplexed kinase inhibitor beads and quantitative mass spectrometry (MIB-MS) to determine baseline kinase expression and adaptive kinome responses to therapy in PDAC PDX tumors. A total of 381 kinases were identified across all samples and tumor specific kinases were isolated by alignment to human peptides. Distinct kinase expression profiles were observed for basal-like and classical tumors. Basal-like tumors showed high expression of kinases involved in receptor tyrosine kinase activity, MAP kinase activity, and clathrin-dependent endocytosis. Classical subtype tumors showed increased expression of kinases involved in metabolism and cytoskeletal regulatory kinases. Differential protein expression was further validated by differential gene expression using RNAseq. MIB profiling of kinome response to EGFR inhibition by erlotinib indicated kinome reprogramming with upregulation of microtubule associated kinases and MAP kinase family members. Overall, these results suggest that basal-like and classical subtype tumors exhibit distinct kinome profiles that present possible subtype specific vulnerabilities to kinase inhibition. Stratifying kinase inhibitor therapies based on tumor subtype could improve response to targeted therapies in PDAC. Citation Format: Yi Xu, Michael East, Ashley Morrison, Gabriela Herrera, Laura Peng, Gary Johnson, Jen Jen Yeh. Proteomic profiling reveals subtype specific kinase expression in pancreatic cancer [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-079.
Abstract 8902: The High Circulating Leptin is Associated With Increased Mortality Risk in Stable Coronary Heart Disease Patients
Authors: Otto Mayer, Jan Bruthans, Jitka Seidlerová, Julius Gelžinský, Radek Kucera
Journal: Circulation (2021)

Introduction: Leptin is an adipocyte-derived peptide, involved in energy homeostasis and regulation of body weight. The position of leptin in cardiovascular pathophysiology remained controversial, some studies suggest a detrimental effect of hyperleptinemia on the cardiovascular (CV) system, while others assume the role of leptin as protective. Hypothesis: We explore whether high leptin status affects the mortality/ morbidity risk in stable patients with coronary heart disease. Methods: 975 patients, ≥6 months after myocardial infarction (EUROASPIRE cohort) were followed in a prospective study. All-cause or CV death, non-fatal events (myocardial infarction, stroke or any revascularization) and hospitalizations for heart failure (HF) were registered as outcomes Results: High serum leptin concentrations (≥18.9 ng/mL, i.e. 4 th quartile) indicate inferior survival, as well as a higher incidence of fatal vascular event or hospitalizations for HF ( see Figure). Even after full adjustment for potential covariates, high leptin was associated with significantly increased 5-years risk of all-cause death [HRR 2.10 (95%CIs:1.29-3.42), p&lt;0.003], CV death [HRR 2.65 (95%CIs:1.48-4.74), p&lt;0.001] and HF hospitalization [HRR 1.95 (95%CIs:1.11-3.44), p&lt;0.020]. In contrast, the incidence risk of non-fatal CV events was only marginally and non-significantly influenced [HRR 1.27 (95%CIs:0.76-2.13), p=0.359] Conclusions: High leptin concentration entails an increased risk of mortality (apparently driven by fatal CV events) and future worsening of HF, on top of conventional CV risk factors and the baseline status of left ventricular function.